Login to Your Account

Clinic Roundup

Tuesday, August 28, 2012

• Debiopharm Group, of Lausanne, Switzerland, treated its first patient in an open-label, Phase III trial of triptorelin pamoate 22.5 mg 6-month formulation in children with central precocious puberty. The study will enroll 44 children from the U.S., Chile and Mexico, with a primary objective of evaluating safety and efficacy in reducing luteinizing hormone to prepubertal levels after six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription